Pod24 and Cr30 Are Promising Surrogate Endpoints for Assessing the Outcome of Patients With Advanced Stage Follicular Lymphoma Enrolled in the Foll05 Trial by Fil.
Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_91
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
Wiley